CD274 and neoplasm: Indeed, the use of pembrolizumab in first-line treatment of aNSCLC patients with a programmed death ligand 1 (PD-L1) tumor proportion score of 50% or greater led to an estimated median overall survival (OS) of 30 months within clinical trials [8].